CompletedPhase 2NCT02607631

A Study of Pembrolizumab for Patients With Thymic Epithelial Tumor

Studying Thymic epithelial neoplasm

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Samsung Medical Center
Principal Investigator: Myung-Ju Ahn, Prof.
Samsung Medical Center
Intervention: Pembrolizumab(drug)
Enrollment: 33 enrolled
Eligibility: 18 years · All sexes
Timeline: 2015 – 2018

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02607631 on ClinicalTrials.gov

Other trials for Thymic epithelial neoplasm

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE2NCT06311955
Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor
Jian Chen
RECRUITINGNANCT05558644
Characterisation of the Immune Infiltrate and Molecular Features of Thymic Epithelial Tumors Tumors (TETs) (IMMUNO-TET)
Institut Curie

See all trials for Thymic epithelial neoplasm →

← Back to all trials